SOPHiA GENETICS (NASDAQ:SOPH) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of SOPHiA GENETICS (NASDAQ:SOPH) in a report published on Monday,Benzinga reports. HC Wainwright currently has a $14.00 price target on the stock.

Other equities analysts have also recently issued research reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Finally, BTIG Research raised their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, SOPHiA GENETICS has an average rating of “Hold” and a consensus price target of $10.00.

SOPHiA GENETICS Stock Down 2.6%

Shares of SOPHiA GENETICS stock opened at $7.22 on Monday. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58. The company’s fifty day simple moving average is $7.94 and its two-hundred day simple moving average is $6.18. The company has a market cap of $605.69 million, a P/E ratio of -6.28 and a beta of 0.95. SOPHiA GENETICS has a 12-month low of $3.75 and a 12-month high of $8.98.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. The company had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. Research analysts anticipate that SOPHiA GENETICS will post -0.77 EPS for the current year.

Insider Buying and Selling

In other SOPHiA GENETICS news, CTO Abhimanyu Verma sold 5,284 shares of the stock in a transaction on Monday, October 5th. The stock was sold at an average price of $8.12, for a total value of $42,906.08. Following the completion of the transaction, the chief technology officer owned 166,887 shares in the company, valued at approximately $1,355,122.44. This represents a 3.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Chairman Jurgi Camblong sold 40,172 shares of the firm’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $8.13, for a total value of $326,598.36. Following the transaction, the chairman directly owned 3,395,650 shares of the company’s stock, valued at $27,606,634.50. This represents a 1.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 282,543 shares of company stock valued at $2,130,026 over the last 90 days. 4.88% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. AWM Investment Company Inc. bought a new stake in SOPHiA GENETICS during the second quarter worth about $9,809,000. Principal Financial Group Inc. grew its holdings in SOPHiA GENETICS by 0.7% in the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after purchasing an additional 9,800 shares during the period. Hodges Capital Management Inc. bought a new position in shares of SOPHiA GENETICS during the first quarter valued at approximately $2,157,000. Sei Investments Co. bought a new position in shares of SOPHiA GENETICS during the first quarter valued at approximately $1,772,000. Finally, 1492 Capital Management LLC increased its stake in shares of SOPHiA GENETICS by 8.4% during the first quarter. 1492 Capital Management LLC now owns 225,751 shares of the company’s stock valued at $1,117,000 after purchasing an additional 17,406 shares in the last quarter. 31.59% of the stock is currently owned by institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.